The Possibility of Radiotherapy as Downstaging to Living Donor Liver Transplantation for Hepatocellular Carcinoma With Portal Vein Tumor Thrombus
TO THE EDITOR:
Hepatocellular carcinoma (HCC), the most common type of primary liver cancer, is the third leading cause of cancer-related death worldwide, especially in developing countries. (1, 2) Advanced HCC with portal vein tumor thrombosis (PVTT) is not easy to manage because it is often multifocal and thus unresectable and is still considered to be a contraindication of liver transplantation (LT). (3) According to the Barcelona Clinic Liver Cancer criteria, sorafenib is proposed as the first-line treatment in patients with remnant liver function, but its result remains dismal with an extension of median survival from 4.2 to 6.5 months in an Asia-Pacific trial and from 7.9 to 10.2 months in the Sorafenib HCC Assessment Randomized Protocol trial. (4) (5) (6) Traditionally, radiation therapy (RT) was believed to be not effective for HCC, but after the development of the conformal radiation therapy (CRT), it has been shown to be effective. The potential as a bridge therapy or downstaging prior to LT has been proposed. (7) (8) (9) (10) A recent study reported that 1-year, 3-year, and 5-year recurrence-free survival (RFS) rates were 63.6%, 45.5%, and 45.5% after living donor liver transplantation (LDLT) in HCC patients with PVTT without any downstaging. (11) It showed acceptable results in a small number of patients. Nevertheless, they suggest that LDLT is not an absolute contraindication in selective PVTT patients.
Despite these clinical trials for PVTT, there is still no report about RT as a downstaging procedure for LDLT, and PVTT is considered incurable. Because of its expected poor outcome and limited organ resources, organs from deceased donors are not allocated to patients with PVTT. LDLT on the other hand may be considered as an option for this group of patients wishing to receive LT after successful downstaging.
The purpose of our study was to evaluate the possibility of applying LDLT following successful downstaging using RT in advanced HCC with PVTT. Furthermore, a propensity score matching was done with patients who have undergone RT without LT in order to evaluate the effect of LDLT following RT downstaging.
Abbreviations: AFP, alpha-fetoprotein; ALT, alanine aminotransferase; AP score, AFP*PIVKAII; CMV, cytomegalovirus; CR, complete response; CRT, conformal radiation therapy; CT, computed tomography; CTP, Child-Turcotte-Pugh; DFS, disease-free survival; ES grade, Edmondson-Steiner nuclear grade; HCC, hepatocellular carcinoma; H-J, hepaticojejunostomy; LDLT, living donor liver transplantation; LPV, left portal vein; LT, liver transplantation; MELD, Model for End-Stage Liver Disease; mRECIST, modified Response Evaluation Criteria in Solid Tumors; MRI, magnetic resonance imaging; mTORi, mammalian target of rapamycin inhibitor; NA, not available; OS, overall survival; P3, segment 3 portal vein; P7, segment 7 portal vein; P8, segment 8 portal vein; PD, progressive disease; PET, positron emission tomography; PIVKA-II, protein induced by vitamin K absence or antagonist II; PR, partial response; PRBC, packed red blood cells; PVTT, portal vein tumor thrombosis; RFA, radiofrequency ablation; RFS, recurrence-free survival; RPV, right portal vein; RT, radiation therapy; SD, stable disease; TACE, transarterial chemoembolization; TARE, transarterial radioembolization. 
CHOI ET AL. LIVER TRANSPLANTATION, April 2017

Patients and Methods
Between May 1996 and March 2013, a total of 1360 patients underwent LT at our institution. Among them, 5 recipients with advanced PVTT who received RT prior to LDLT were included in the study. All of these recipients were Child-Pugh classification A patients before RT, and donors were the recipient's immediate family. Baseline demographics with tumor characteristics are shown in Tables 1 and 2 . According to our institution's protocol, the hepatologist made a decision to use transarterial chemoembolization (TACE)/transarterial radioembolization (TARE)/RT/LT in all HCC patients with a multidisciplinary tumor board consisting of a hepatologist, radiologist, interventional radiologist, radiation oncologist, and a liver surgeon who monitored and recorded the results of the treatment. Vp4 type of PVTT according to the Liver Cancer Study Group of Japan (presence of a tumor thrombus in the main trunk of the portal vein or a portal vein branch contralateral to the primarily involved lobe, or both), PVTT patients were excluded from LDLT. In case LDLT was considered, the transplant surgeon informed the patient about the higher risk of tumor recurrence following LDLT along with the consequences when no LDLT would be done.
A second group of 10 patients who received RT alone were matched using propensity score according to sex, age, tumor size and number, dose of RT, level of alpha-fetoprotein (AFP), and the extent of PVTT to compare the outcome (Table 3) . PVTT was diagnosed by computed tomography (CT) and/or magnetic resonance imaging (MRI) before RT.
Both groups of patients received CRT after January 2008 and before CRT. There was no evidence of extrahepatic metastasis proven by CT and/or MRI and/or positron emission tomography (PET) scan. Objective tumor response was evaluated after 3 months with CT and/or MRI according to the modified Response Evaluation Criteria in Solid Tumors (mRECIST) criteria. Overall survival (OS) and disease-free survival (DFS) were analyzed. According to our institution's RT protocol, patients were evaluated once a week during radiation treatment and at 1 and 3 months after completion of RT.
MODALITY OF RT
According to our institution's protocol, CRT was defined as "three-dimensional conformal radiotherapy" that makes it possible to deliver higher doses to the tumor, while minimizing the irradiation of normal liver tissue, (12) and is performed at scheduled intervals of TACE followed by RT. (13) In short, 8 days after the first TACE was performed, patients underwent pre-RT clinical examinations, including a physical examination, blood tests, and liver function tests. If the results indicated that the patient was fit to undergo RT, then RT simulation was done and RT was initiated on day 14 after TACE. If aspartate aminotransferase/alanine aminotransferase levels were elevated 3-fold or more above normal levels and/or the ChildPugh score was elevated 2 or more at 1 week after TACE, then RT was delayed by 1 week. Indications of RT were unresectable HCC for which TACE alone was expected to be ineffective, clinical liver function with Child-Pugh classification A or B, a life expectancy of more than 12 weeks, and no previous history or treatment for any other malignancy. (13) All patients had simulation 4-dimensional CT (General Electric, Milwaukee, WI) with contrast enhancement, and patients were trained for regular, shallow breathing. The total radiation dose was determined by our institution's guideline. (14) STATISTICAL ANALYSIS Continuous variables are presented as the median value, the mean 6 standard deviation, or both, whereas categorical variables are presented as numbers and percentages. Calculations of P values were performed using the Mann-Whitney U test for continuous variables and Fisher's exact test for categorical variables. A P value of 0.05 was considered significant for study purposes. OS was analyzed by the Kaplan-Meier method using the log-rank test. All analyses were performed using PASW statistics 21 (formerly SPSS Statistics).
Results
CHARACTERISTICS OF LDLT FOLLOWING RT AND RT ALONE PATIENTS
The clinical characteristics of both groups are summarized in Table 3 . Propensity score matching was done with age, sex, tumor size and number, extent of PVTT, dose of RT, and levels of AFP. In the LDLT following RT group, 4 recipients had TACE between RT and LDLT, and in the RT alone group, 3 patients had TACE, and 4 patients had radiofrequency ablation (RFA) for locoregional control. To evaluate the tumor response for RT, serum AFP level and an image study with CT and/or MRI were checked before and 3 months after RT. In the LDLT following RT group, there were 2 patients with disease progression after RT, but in the RT alone group, all patients were shown a good response to RT (above stable disease [SD]).
SAFETY OF LDLT FOLLOWING RT
The indication of LDLT was liver failure in 4 patients and HCC recurrence in 1 patient. The interval period between RT and LT was 180 days, and Model for End-Stage Liver Disease (MELD) score was 18. Mean operation time was 588 minutes, and a mean of 3.4 units of red blood cells were transfused. There was no perioperative mortality, and biliary anastomosis was done by duct-to-duct anastomosis in all patients (Table 4) . Two patients had bile leakage, and the other 2 patients developed strictures. All leakages were managed by percutaneous drainage insertion, and all strictures were managed by endoscopic retrograde biliary drainage. One infection was a cytomegalovirus (CMV) infection and that was cured by ganciclovir. 
VALUE OF LDLT FOLLOWING RT FOR PVTT
Only 2 patients in the LDLT following RT group developed HCC recurrence, whereas all patients in the RT alone group showed tumor progression and/or extrahepatic metastasis during follow-up ( Table 5) . The 1-and 3-year survival rates were 50% and 30%, respectively, for RT alone compared with 100% and 80% for LDLT following RT (Table 5) . Furthermore, according to the OS analysis by the Kaplan-Meier method using the log-rank test, the LDLT following RT group had a survival gain with a statistically significant difference (P < 0.009; Fig. 1 ).
Discussion
Patients with HCC and PVTT are not accepted as LT candidates due to a high recurrence rate following LT. There were trials attempting downstaging in these patients using TARE with Yttrium-90 or multimodal treatment with sorafenib, but the results were still not satisfactory. (15, 16) The role of RT had been restricted in the past due to radiation-induced liver disease caused by low tolerance of the liver to radiation but after the introduction of CRT, excessive radiation exposure to the liver and adjacent organs could be avoided, and radiation treatment has become a safer treatment modality. (17, 18) Despite the small number of patients, our data suggest the possible role of RT as a new treatment modality for downstaging patients with PVTT. According to Lee et al., patients with main portal vein invasion, AP score (AFP*PIVKAII) > 20,000, hypermetabolic lesions in PET scan, or an original tumor >7 cm should not be eligible for LDLT due to the high recurrence rate. (11) In 1 patient, the size of the tumor was reduced to 2.5 from 7.5 cm, but PET scan uptake remained hypermetabolic and eventually recurred. However, 1 patient had a high level of AFP, protein induced vitamin K absence or antagonist II (PIVKA-II), AP score (908 ng/mL, 500 ng/mL, and 454,000, respectively) and 2 patients showed hypermetabolic lesions at initial presentation. In these 3 patients, RT was successful in "biologically" down-staging to low AFP and isometabolic lesions, and none of them showed recurrence following LDLT. We therefore believe that although RT may not down-stage all PVTT patients, it may be useful in selected patients who are responsive to RT and afford expanded selection criteria to patients who would initially have a high chance of recurrence.
Additionally, our data show that the response to RT should not be evaluated by mRECIST criteria but rather by using biological factors such as AFP, PIVKA-II, and/or PET scan uptake as suggested by Lee et al. According to mRECIST criteria, among recurrent patients, 1 patient showed progressive disease (PD), and 1 showed complete response (CR). Among nonrecurrent patients, there was 1 PD, SD, and CR each. However, all patients with no recurrence were within Lee's criteria.
Despite the possible role of RT as a method to improve RFS rate after LDLT, our data demonstrate that RT alone can only afford control of the tumor and not eradication and thus should be followed by LT in downstaged patients. In RT alone patients, the 1-year and 2-year survival rates were only 50% and 30% even though 80% had CR or partial response (PR) after 3 months. We therefore suggest that HCC patients with less than Vp4 PVTT should undertake counseling for possible LDLT in case the tumor shows good response to RT. Although radiation is known to damage the microvascular structures, our previous experience with a higher-dose exposure of hypofractionated RT showed that biliary complications in nonanastomosed bile ducts were minimal. (19) We had also taken optimal care to preserve all vasculature around the hilar plate during duct-to-duct anastomosis. However, we had an 80% biliary complication rate, which is 4 times higher than our previously reported biliary complication rate. (20) We therefore suggest that hepaticojejunostomy (H-J) should be done rather than duct-to-duct anastomosis in all patients with a previous history of RT to reduce the bile duct complication rate. (21) Our study has obvious limitations. It is a retrospective data collection from a small group of patients without a formally planned treatment algorithm where all the decisions were made through a multidisciplinary group of experts on a case-by-case basis. It therefore reflects the results of a highly selected group of patients which may be biased. Nevertheless, we hope our data may open the gates to a new treatment modality by a multidisciplinary approach that could ensure a potential cure for patients still thought to be untreatable by any single treatment means.
RT alone will not result in longterm survival, and LDLT should be performed after RT in order to provide a longterm survival benefit. An acceptable result is possible in a selected group of patients with Vp3 PVTT who show good biological tumor response to RT. H-J is recommended rather than duct-to-duct anastomosis to prevent biliary complications.
